RedHill Biopharma Ltd is a drug manufacturers-specialty & generic business based in the US. RedHill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. RedHill Biopharma employs 182 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in RedHill Biopharma
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RDHL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
RedHill Biopharma stock price (NASDAQ: RDHL)Use our graph to track the performance of RDHL stocks over time.
RedHill Biopharma shares at a glance
|Latest market close||$7.25|
|52-week range||$5.90 - $11.52|
|50-day moving average||$6.78|
|200-day moving average||$7.45|
|Wall St. target price||$20.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.47|
Buy RedHill Biopharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy RedHill Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
RedHill Biopharma price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||3.87%|
|3 months (2021-04-30)||6.30%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
RedHill Biopharma financials
|Revenue TTM||$83.9 million|
|Gross profit TTM||$28.3 million|
|Return on assets TTM||-22.01%|
|Return on equity TTM||-169.37%|
|Market capitalisation||$300.9 million|
TTM: trailing 12 months
Shorting RedHill Biopharma shares
There are currently 2.1 million RedHill Biopharma shares held short by investors – that's known as RedHill Biopharma's "short interest". This figure is 9.7% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting RedHill Biopharma shares can be evaluated.
RedHill Biopharma's "short interest ratio" (SIR)
RedHill Biopharma's "short interest ratio" (SIR) is the quantity of RedHill Biopharma shares currently shorted divided by the average quantity of RedHill Biopharma shares traded daily (recently around 260842.55050505). RedHill Biopharma's SIR currently stands at 7.92. In other words for every 100,000 RedHill Biopharma shares traded daily on the market, roughly 7920 shares are currently held short.
However RedHill Biopharma's short interest can also be evaluated against the total number of RedHill Biopharma shares, or, against the total number of tradable RedHill Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RedHill Biopharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 RedHill Biopharma shares in existence, roughly 40 shares are currently held short) or 0.0657% of the tradable shares (for every 100,000 tradable RedHill Biopharma shares, roughly 66 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against RedHill Biopharma.
Find out more about how you can short RedHill Biopharma stock.
RedHill Biopharma share dividends
We're not expecting RedHill Biopharma to pay a dividend over the next 12 months.
RedHill Biopharma share price volatility
Over the last 12 months, RedHill Biopharma's shares have ranged in value from as little as $5.9 up to $11.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RedHill Biopharma's is 1.42. This would suggest that RedHill Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
RedHill Biopharma overview
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. .
Stocks similar to RedHill Biopharma
RedHill Biopharma in the news
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
RedHill Biopharma files $200M mixed securities shelf
RedHill Settles Movantik(R) Apotex Patent Litigation
Frequently asked questionsWhat percentage of RedHill Biopharma is owned by insiders or institutions?
Currently 0.049% of RedHill Biopharma shares are held by insiders and 25.794% by institutions. How many people work for RedHill Biopharma?
Latest data suggests 182 work at RedHill Biopharma. When does the fiscal year end for RedHill Biopharma?
RedHill Biopharma's fiscal year ends in December. Where is RedHill Biopharma based?
RedHill Biopharma's address is: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921 What is RedHill Biopharma's ISIN number?
RedHill Biopharma's international securities identification number is: US7574681034 What is RedHill Biopharma's CUSIP number?
RedHill Biopharma's Committee on Uniform Securities Identification Procedures number is: 757468103
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert